[Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis]. - Abstract - Europe PMC
Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help …

Background Not all patients with rheumatoid arthritis can tolerate or respond to
methotrexate, a standard treatment for this disease. There is evidence that antitumour …

The approval of the monoclonal antitumour necrosis factor antibody, infliximab, for the
treatment of rheumatoid arthritis (RA) in 1999, occurring almost simultaneously with that of …

Cytokines play a central part in the human immune response and can generally be
categorised as proinflammatory or anti-inflammatory cytokines in nature. Tumour necrosis …

Background Infliximab is a human murine chimeric anti‐tumour necrosis factor alpha
monoclonal antibody recently approved for the treatment of refractory RA. Objectives To …

Objective: To evaluate the efficacy of switching to etanercept treatment in patients with
rheumatoid arthritis who already responded to infliximab, but presented side effects …

Background CT-P13 was developed as a biosimilar product to infliximab (Remicade®), a
chimeric monoclonal antibody approved in the European Union in 1999 for the treatment of …

Background CT-P13 is a biosimilar product of infliximab (INX). Data up to week 30 has been
reported at EULAR 2012. 1 Objectives To compare the efficacy and safety of CT-P13 and …

Currently, infliximab is given for disease control for active rheumatoid arthritis (RA) patients
despite methotrexate treatment. However, the efficacy and safety of infliximab in Korean …

Background: Because of its long-term effectiveness in clinical practice, methotrexate (MTX)
is currently the preferred disease-modifying antirheumatic drug (DMARD) for patients with …